Understanding regulation of cell growth in childhood brain tumors

Current Opinion in Pediatrics

Volumn 10, Issue 6, 1998, Pages 551-555

  Khakoo, Yasmin ^a   Rosenfeld, Myrna R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN TUMOR; CELL CYCLE; CELL DIVISION; CELL GROWTH; CHILDHOOD CANCER; GENE MUTATION; GROWTH REGULATION; HUMAN; NEUROFIBROMATOSIS; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; TUBEROUS SCLEROSIS;

EID: 0031742789     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199810060-00002     Document Type: Review

References (49)

1. Duffner P, Cohen M, Meyers M, Heise H: Survival of children with brain tumors: SEER program 1971-1980. Neurology 1986, 36:597-601.
2. Gurney J, Severson R, Davis S, Robison L: Incidence of cancer in young children in the United States. Cancer 1995, 75:2186-2195.
3. Young J, Miller R: Incidence of malignant tumors in US children. J Pediatr 1975, 86:254-258.
4. Glauser T, Packer R: Cognitive deficits in long-term survivors of childhood brain tumors. Childs Nerv Syst 1991, 7:2-12.
5. Yang T, Wong T, Cheng L, Chang T, Hsu T, Chen S, Chuang T: Neuropsychological sequelae after treatment for medulloblastoma in childhood-the Taiwan experience. Childs Nerv Syst 1997, 13:77-80.
6. Dirks PB, Rutka JT: Current concepts in neuro-oncology: The cell cycle-a review. Neurosurgery 1997, 40:1000-1015. The authors provide a comprehensive review of cell cycle regulation with particular focus on the role of cyclin-dependant kinases, p15/16 (multitumor suppressor gene), and retinoblastoma on the development of malignant brain tumors.
7. Hartwell L, Weinert T: Checkpoints. Controls that ensure the order of cell cycle events. Science 1989, 246:629-633.
8. Marshall C: Tumor suppressor genes. Cell 1991, 64:313-326.
9. Weinberg R: Tumor suppressor genes. Science 1991, 254:1138-1146.
10. Weinberg R: Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989, 49:3713-3721.
11. Levine A, Schmidek H: Molecular genetics of nervous system tumors. 1993, New York: Wiley-Liss.
12. Friend S, Horowitz J, Gerber M, Wang X, Bogenmann E, Li F, Weinberg R: Deletions of a DNA sequence in retinoblastoma and mesenchymal tumors: Organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A 1987, 84:9059-9063.
13. Li F: Cancer families: Human models of susceptibility to neoplasia. Cancer Res 1988, 48:5381-5386.
14. Berg B: Principles of child neurology. 1996, New York: McGraw-Hill.
15. Listernick R, Louis DN, Packer RJ, Gutmann DH: Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997, 41:143-149. The NF1 Optic Pathway Glioma Task Force was established in 1995 with the goal of developing guidelines for the screening, follow-up, and treatment of children with optic gliomas and neurofibromatosis 1. This article reports the recommendations of the task force and will be of great use to any clinician treating patients with these conditions.
16. Burger P, Scheithauer B: Tumors of the central nervous system. 1994, Washington, DC: Armed Forces Institute of Pathology.
17. Viskochil D, Buchberg A, Xu G, Cawthon R, Stevens J, Wolff R, et al.: Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62:187-192.
18. Wallace M, Marchuk D, Andersen L, Letcher R, Odeh H, Saulino A, et al.: Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181-186.
19. Cawthon R, Weiss M, Xu G, Viskochil D, Culver M, Stevens J, et al.: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990, 62:193-201.
20. Xu G, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al.: The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990, 62:599-608.
21. Martin G, Viskochil D, Bollag G, McCabe P, Crosier W, Haubruck H, et al.: The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990, 63:843-849.
22. Basu T, Gutmann D, Fletcher J, Glover T, Collins F, Downward J: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713-715.
23. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T, Boss G: Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996, 12:507-513.
24. Jacks T, Shih S, Schmitt EM, Bronson RT, Bernards A, Weinberg RA: Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994, 7:353-361.
25. Biegel JA: Genetics of pediatric central nervous system tumors. J Pediatr Hematol Oncol 1997, 19:492-501. In addition to reviewing the genetics of several pediatric nervous system tumors, this article reviews the genetics of some more unusual pediatric tumors, such as atypical teratoid/rhabdoid tumors.
26. The TSC1 Consortium: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808. This paper describes the cloning of the TSC1 gene, the protein product, and identifies gene mutations in patients with tuberous sclerosis.
27. The European Chromosome 16 Tuberosis Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75:1305-1315.
28. Wienecke R, Konig A, DeClue J: Identification of tuberin, the tuberous sclerosis 2 gene product: Tuberin possesses specific Rap1GAP activity. J Biol Chem 1995, 270:16409-16414.
29. Soucek T, Holzl G, Bemaschek G, Hengtschlager M: A role of the tuberous sclerosis gene-2 product during neuronal development. Oncogene 1998, 16:2197-2204. In this study, the authors describe for the first time the role of tuberin, the TSC2 gene product, in neuronal differentiation. These data could potentially explain how alterations in tuberin lead to the tuberous sclerosis complex phenotype.
30. Mizuguchi M, Kato M, Yamanouchi H, Ikeda K, Takashima S: Loss of tuberin from cerebral tissues with tuberous sclerosis and astrocytoma. Ann Neurol 1996, 40:941-944.
31. Yeung RS, Katsetos CD, Klein-Szanto A: Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis. Am J Pathol 1997, 151:1477-1486. The Eker rat was developed as a model for hereditary renal cell carcinoma. It was found that these rats carry a germline mutation of the TSC2 gene. Further studies revealed that these rats develop nervous system lesions similar to the giant cell astrocytomas and hamartomas seen in tuberous sclerosis complex.
32. Jin F, Wienecke R, Xiao G, Maize J, DeClue J, Yeung RS: Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (TSC2) gene and its C-terminal region. Proc Natl Acad Sci U S A 1996, 93:9154-9159.
33. Henske EP, Scheithauer BW, Short MP, Wollman R, Nahmias J, Horngold N, et al.: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996, 59:400-406.
34. Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi M: Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Expt Neurol 1997, 56:782-789.
35. Pollack I, Hamilton R, Finkelstein S, Campbell J, Martinez A, Sherwin R, et al.: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997, 57:304-309.
36. Heideman R, Packer R, Albright L, Freeman C, Rorke L: Tumors of the central nervous system. In Principles and practice of pediatric oncology. Edited by Pizzo P., and Poplack D. Philadelphia: Lippincott-Raven Publishers; 1997:633-697.
37. Emadian SM, McDonald JD, Gerken SC, Fults D: Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res 1996, 2:1559-1564.
38. Batra S, McLendon R, Koo J, Castellino-Prabhu S, Krischer J, Friedman H, et al.: Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995, 24:39-45.
39. Biegel JA, Janss AJ, Raffel C, Sutton L, Rorke LB, Harper JM, Phillips P: Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res 1997, 3:473-478. The use of genetic markers to predict prognosis and treatment outcomes is becoming an important part of standard medical practice. This paper, by presenting results in conflict with earlier studies, points out the need for large and extensive studies prior to using a genetic test in the clinical situation.
40. Gorlin R: Nevoid basal-cell carcinoma syndrome. Medicine 1987, 66:98-113.
41. Farndon P, Morris D, Hardy C, McConville C, Weissenbach J, Kilpatrick M, Reis A: Analysis of 133 meioses places the gene for nevoid basal cell carcinoma (Gorlin) syndrome and Fanconi anemia group C in a 2.6-M interval and contributes to the fine map of 9q22.3. Genomics 1994, 23:486-489.
42. Wicking C, Berkman J, Wainwright B, Chenevix-Trench G: Fine genetic mapping of the gene for nevoid basal cell carcinoma syndrome. Genomics 1994, 22:505-511.
43. Johnson R, Rothman A, Xie J, Goodrich L, Bare J, Bonifas J, et al.: Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Nat Genet 1996, 272:1668-1671.
44. Hooper J, Scott M: The Drosophila patched gene encodes a putative membrane protein required for segmental patterning. Cell 1989, 59:751-765.
45. Ingham P, Taylor A, Nakano Y: Role of Drosophila patched gene in positional signalling. Nature 1991, 353:184-187.
46. Ingham P: Pattern formation: Hedgehog points the way. Curr Biol 1994, 4:347-350.
47. Raffel C, Jenkins R, Fredenck L, Hebrink D, Alderete B, Fults D, James C: Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997, 57:842-845. The patched gene has been extensively studied in Drosophila, where it functions as a developmental regulator. The human homolog PTCH functions in a similar manner. The finding that PTCH is mutated in some medulloblastomas suggests potential etiologic mechanism of tumorigenesis.
48. Goodrich LV, Milenkovic L, Higgins KM, Scott MP: Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997, 277:1109-1113. To further study the role of PTCH in medulloblastoma development, these authors developed a mouse model in which the PTCH gene was inactivated.
49. Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzica T, Lichter P, Reifenberger G: Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998, 58:1798-1803. In addition to PTCH mutations, this study shows that some primitive neuroectodermal tumors and basal cell carcinomas contain mutations in other related genes, supporting the notion that carcinogenesis is the result of the accumulation of multiple genetic alterations.